AC Immune (ACIU) Expected to Announce Earnings on Thursday

AC Immune (NASDAQ:ACIU) is projected to post its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.1440 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 12:30 PM ET.

AC Immune Trading Down 2.4%

NASDAQ ACIU opened at $2.84 on Thursday. The stock has a market cap of $285.16 million, a PE ratio of -3.38 and a beta of 1.64. AC Immune has a 12 month low of $1.43 and a 12 month high of $4.00. The company’s 50-day moving average price is $3.19 and its 200-day moving average price is $2.99.

Hedge Funds Weigh In On AC Immune

Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC lifted its holdings in AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of AC Immune by 20.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock valued at $670,000 after acquiring an additional 36,353 shares during the period. Marshall Wace LLP bought a new position in shares of AC Immune in the 4th quarter worth $586,000. Sei Investments Co. purchased a new stake in shares of AC Immune during the 2nd quarter worth $51,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of AC Immune during the 3rd quarter worth $63,000. Institutional investors own 51.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on ACIU. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, AC Immune presently has a consensus rating of “Hold” and an average price target of $10.00.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.